Should You Buy the Dip in Intellia Therapeutics Stock? [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
Gene-editing is not just science but rewriting life itself. For clinical-stage companies, one successful trial can mean validation, funding, and survival, while one failure can send years of research crashing down overnight. That's exactly what happened with Intellia Therapeutics (NTLA). Once a rising star in CRISPR innovation, the company's story took a tragic turn when an elderly patient in the firm's MAGNITUDE Phase III trial passed away following severe liver complications. The patient, dosed with Intellia's therapy candidate nexiguran ziclumeran (nex-z), showed elevated enzyme levels weeks after treatment. The U.S. Food and Drug Administration (FDA) swiftly imposed a full clinical hold, halting both MAGNITUDE studies and shaking confidence across the gene-editing world. More News from Barchart I'm Preparing for a ‘Bang' When the Nasdaq Crashes. Here's How I'm Trading the QQQ ETF First. Michael Burry Accuses Meta Platforms of ‘Common Fraud' and Inflated Earnings. Should Yo
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]Seeking Alpha
- Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 8-K
- NTLA's page on the SEC website